Welcome to our dedicated page for ORGENESIS news (Ticker: ORGS), a resource for investors and traders seeking the latest updates and insights on ORGENESIS stock.
Orgenesis Inc. (NASDAQ: ORGS) is a pioneering biotech company focused on unlocking the potential of cell and gene therapies (CGTs). Headquartered in White Plains, New York, Orgenesis specializes in autologous therapies, employing a closed and automated processing system designed for compliant production close to the patient, enhancing the efficiency of treatments at the point of care (POCare).
The company operates through two main segments: Octomera and Therapies. Octomera is the company's decentralized cell therapy platform, which has been fundamental in their approach to CGT production. Their decentralized model allows for the integration of academia, hospitals, and industry partners to expedite the commercialization of these therapies. This approach not only reduces costs but also improves patient outcomes by bringing processing services closer to the patient.
Despite industry challenges in 2023, Orgenesis remains steadfast in its mission. CEO Vered Caplan highlighted the growing demand for decentralized cell therapy solutions due to cost pressures and patient demand. Orgenesis has seen support from regulators like the FDA and EMEA, who are progressing guidelines for decentralized production. These advancements have solidified the company’s strategic advantage in handling the development and regulatory processes of their products.
On the financial front, Orgenesis has made significant strides. The recent appointment of Victor Miller as CFO has brought renewed focus on their financial strategy, leveraging their robust cell processing expertise to secure their position in the life sciences sector. Their collaboration with Metalmark has provided critical support, aiding in navigating the biotech industry's fluctuations.
Orgenesis is also at the forefront of developing therapeutic exosomes through their EXOFASTTRACK project. This project aims to accelerate the clinical evaluation of therapeutic exosomes, providing a scalable and cost-effective production process that can revolutionize the field of advanced therapy medicinal products (ATMPs).
Furthermore, Orgenesis has strengthened its infrastructure through a strategic partnership with Germfree. This collaboration focuses on advancing Orgenesis’ therapeutic programs and cell processing services, aiming to make CGTs more accessible and affordable globally. The partnership also includes marketing Orgenesis' decentralized Octomera service platform and its Mobile Processing Units and Labs (OMPULs™).
Orgenesis continues to innovate and expand its global footprint, committed to bringing life-saving therapies to market faster and more efficiently. Their decentralized approach and strategic collaborations position them as leaders in transforming how cell and gene therapies are developed and delivered.
For more information, please visit www.orgenesis.com.
Orgenesis (NASDAQ: ORGS) has successfully placed its first Orgenesis Mobile Processing Unit and Lab (OMPUL) in Europe at the Hospital Infantil Universitario Niño Jesús in Madrid, marking a key milestone in their collaboration. The OMPUL is designed for processing Tumor Infiltrating Lymphocytes (TILs) and Mesenchymal Stem Cells (MSCs). Its operational capability is expected to reduce development and manufacturing costs significantly for cell therapies, including the Celyvir therapy. This initiative aligns with Orgenesis' goal to enhance access to cell and gene therapies at the point of care.
Orgenesis Inc. has announced a partnership with Johns Hopkins University to launch a cell and gene therapy processing facility in Maryland. The project, supported by a $5 million grant from the state, aims to enhance point of care capabilities and is expected to become operational by Q2 2023. The new 7,000-square-foot facility will streamline treatment processes and reduce reliance on outsourcing by connecting with Orgenesis Mobile Processing Units. The center will house 30 Orgenesis employees and expedite clinical trials for innovative therapies.
Orgenesis (NASDAQ: ORGS) announced that its joint venture (JV) with Theracell in Greece has been designated a “Priority Investment of Strategic National Importance” by the Greek government. This status allows the JV to enter a fast-track licensing process to advance cell and gene therapies. Additionally, the JV can request up to €32 million in grants to support development and manufacturing using Orgenesis Mobile Processing Units. The initiative aims to enhance access to affordable therapies targeting serious diseases in Greece.
Orgenesis (NASDAQ: ORGS) has formed a collaboration with Tel Aviv Sourasky Medical Center to establish a point-of-care cell therapy center at Ichilov Hospital, Israel. The agreement focuses on advancing clinical development and validation of Orgenesis’ CD19 CAR-T therapies, including CAR-T derived exosome products. The partnership will utilize Orgenesis' Mobile Processing Units and Labs (OMPULs) to support research and validation activities, aiming to reduce therapy production costs and accelerate clinical development at the point of care.
Orgenesis reported significant financial growth for Q3 2021, with revenue rising to $28.6 million compared to $5.3 million in Q3 2020. The CEO emphasized the advancement of their POCare Platform, designed to address industry challenges like capacity and cost. The company is expanding its global network, collaborating with top institutions to integrate over 30 therapies in areas such as immuno-oncology and auto-immune diseases. A conference call to discuss these developments is scheduled for 8:30 AM ET today.
Orgenesis Inc (NASDAQ: ORGS) announced a conference call scheduled for 8:30 AM ET on November 4, 2021, to discuss corporate progress and recent developments. The call can be accessed via telephone or through a webcast. A replay will be available post-call on the Company’s Investor Events website. Orgenesis specializes in cell and gene therapies, leveraging its POCare Platform to deliver affordable and accessible treatment solutions at the point of care. This framework includes licensed therapeutics, automated technology systems, and a collaborative network aimed at enhancing patient care.
Orgenesis (NASDAQ: ORGS) has partnered with Savicell Diagnostics to enhance its cell and gene therapy platform. This collaboration aims to develop diagnostic kits for quality control and monitoring, new assays to boost potency, and companion diagnostics for patient targeting. Orgenesis gains exclusive rights to use and sell Savicell’s ImmunoBiopsy™ technology, initially focusing on lung cancer. This partnership seeks to increase the efficacy of therapies and ensure consistency in manufacturing processes, representing a significant advancement in Orgenesis' mission to innovate in the biotech sector.
Orgenesis Inc. (NASDAQ:ORGS) will present at the SNN Network Summer Virtual Event 2021 on August 19, 2021, at 8:00 AM ET. CEO Vered Caplan will lead the presentation and engage with investors. The event is accessible via webcast and requires registration for 1x1 investor meetings. Recorded webcasts will also be available afterward. Orgenesis focuses on cell and gene therapies, utilizing its POCare Platform for efficient, decentralized production and improved patient access.
Orgenesis Inc. (NASDAQ: ORGS) reported a remarkable increase in POCare revenues, surging to $10.5 million for Q2 2021, a more than six-fold rise from $1.75 million in Q2 2020. This growth is attributed to enhanced technology transfer and expansion of partnerships within its POCare network. The company aims to address industry bottlenecks in cell and gene therapy production by offering a decentralized supply model. Orgenesis continues adding advanced clinical trials and expanding its global partnerships, including collaborations with notable healthcare institutions like Johns Hopkins University.
On August 3, 2021, Orgenesis Inc (NASDAQ: ORGS) announced a conference call scheduled for August 5, 2021, at 8:30 AM ET to discuss corporate progress and developments. Interested parties can join via telephone or access a webcast. A replay will be available on the company’s Investor Events section until August 5, 2022. Orgenesis is a biotech firm focused on cell and gene therapies, utilizing its POCare Platform to enhance the accessibility and affordability of these therapies globally.
FAQ
What is the current stock price of ORGENESIS (ORGS)?
What is the market cap of ORGENESIS (ORGS)?
What is Orgenesis Inc.'s primary focus?
Where is Orgenesis Inc. headquartered?
What are the main business segments of Orgenesis Inc.?
What is the Octomera platform?
Who is the CEO of Orgenesis Inc.?
What strategic partnership did Orgenesis recently announce?
How does Orgenesis contribute to the development of therapeutic exosomes?
What is the significance of Orgenesis' decentralized approach?
How has Orgenesis addressed the challenges in the biotech industry?
Where can I find more information about Orgenesis?
